Moexipril Improves Renal Ischemia/Reperfusion Injury in Adult Male Rats


  • Esraa H. Alsaaty Pharmacology Department, Al-Sadr Medical City, Al-Najaf Health Directorate, Najaf, Iraq
  • Ali M. Janabi Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Kufa, Najaf, Iraq



Moexipril, renal ischemia/reperfusion injury (RIRI), inflammatory mediators, oxidative stress, apoptotic factors.


Objective: The goal of this study is to see if moexipril can protect rats against renal ischemia/reperfusion injury.

Methods: Overall twenty-eight males of rats were divided randomly into four groups (7 rat each group). Sham group: Except for ischemia
induction, these rats underwent IP anesthesia and surgery. Induced group: This group rats were anesthetized and given a midline
laparotomy to induce bilateral renal ischemia for 30 min and 2 hours of reperfusion. DMSO group: Rats received DMSO IP injection 30 min
before ischemia and subjected to 30 min bilateral ischemia and reperfusion for 2 hours, DMSO is a vehicle of moexipril and considered as
control. Moexipril group (pretreated group): moexipril was given in a dose 0.3 mg/kg I.P. injection 30 min before ischemia.

Results: Renal IRI as indicated by a significant increase (P < 0.05) in urea, creatinine, NF-KB P65, IL-1β, and caspase-3 level, while GSH,
SOD, and Bcl-2 levels significantly (P < 0.05) reduced in Renal tissues of rats in the induced group compared to sham group. Moexipril
pretreatment significantly (P < 0.05) ameliorate RIRI as suggested from significant lowering in urea, creatinine, and inflammatory markers
(NF-KB P65 and IL-1β). The renal level of oxidative marker (SOD and GSH) and anti-apoptotic marker Bcl-2 were significant decreased
(P < 0.05) and also significantly increase (P < 0.05) in caspase-3 level with moexipril group in comparison to induced group.

Conclusion: By inhibiting oxidative stress, inflammation, and the apoptotic pathway, moexipril significantly protect from renal ischemia
reperfusion in rats.


Hoste, E.A., et al., Global epidemiology and outcomes of acute kidney injury. Nature Reviews Nephrology, 2018. 14(10): p. 607-625.

Makris, K. and L. Spanou, Acute kidney injury: definition, pathophysiology and clinical phenotypes. The clinical biochemist reviews, 2016. 37(2): p. 85.

El-Mokadem, B.M., et al., Epac-1/Rap-1 signaling pathway orchestrates the reno-therapeutic effect of ticagrelor against renal ischemia/reperfusion model. Biomedicine & Pharmacotherapy, 2021. 139: p. 111488.

Wu, M.-Y., et al., Current mechanistic concepts in ischemia and reperfusion injury. Cellular Physiology and Biochemistry, 2018. 46(4): p. 1650-1667.

Garcia, I., et al., Oxidative insults disrupt OPA1-mediated mitochondrial dynamics in cultured mammalian cells. Redox Report, 2018. 23(1): p. 160-167.

Yu, W., et al., Mst1 promotes cardiac ischemia–reperfusion injury by inhibiting the ERK-CREB pathway and repressing FUNDC1-mediated mitophagy. The Journal of Physiological Sciences, 2019. 69: p. 113-127.

Bonventre, J.V. and L. Yang, Cellular pathophysiology of ischemic acute kidney injury. The Journal of clinical investigation, 2011. 121(11): p. 4210-4221.

Han, S.J. and H.T. Lee, Mechanisms and therapeutic targets of ischemic acute kidney injury. Kidney research and clinical practice, 2019. 38(4): p. 427.

Xu, W., et al., Bax-PGAM5L-Drp1 complex is required for intrinsic apoptosis execution. Oncotarget, 2015. 6(30): p. 30017.

Belal, F., et al., Development of membrane electrodes for the specific determination of moexipril hydrochloride in dosage forms and biological fluids. Portugaliae Electrochimica Acta, 2009. 27(4): p. 463-475.

Pines, A. and E.Z. Fisman, ACE inhibition with moexipril: a review of potential effects beyond blood pressure control. American Journal of Cardiovascular Drugs, 2003. 3: p. 351-360.

Torsello, A., et al., Moexipril and quinapril inhibition of tissue angiotensin-converting enzyme activity in the rat: evidence for direct effects in heart, lung and kidney and stimulation of prostacyclin generation. Journal of endocrinological investigation, 2003. 26: p. 79-83.

Brown, N.J., Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nature Reviews Nephrology, 2013. 9(8): p. 459-469.

Anderson, B., et al., Anti-free radical mechanisms in captopril protection against reperfusion injury in isolated rat hearts. The Canadian journal of cardiology, 1996. 12(10): p. 1099-1104.

Ravati, A., et al., Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. European journal of pharmacology, 1999. 373(1): p. 21-33.

Tekin, S., et al., Protective effect of saxagliptin against renal ischaemia reperfusion injury in rats. Archives of Physiology and Biochemistry, 2022. 128(3): p. 608-618.

Hesketh, E.E., et al., Renal ischaemia reperfusion injury: a mouse model of injury and regeneration. JoVE (Journal of Visualized Experiments), 2014(88): p. e51816.

Zhang, J., et al., The anti-inflammatory effects of curcumin on renal ischemia-reperfusion injury in rats. Renal Failure, 2018. 40(1): p. 680-686.

Dong, Y., et al., Ischemic duration and frequency determines AKI-to-CKD progression monitored by dynamic changes of tubular biomarkers in IRI mice. Frontiers in Physiology, 2019. 10: p. 153.

Taheran, E., V. Mohammadi, and R. Mohammadi, Protective Effect of Pyrroloquinoline Quinone (PQQ) against Renal Ischemia-Reperfusion Injury in Rat. Iranian Journal of Veterinary Surgery, 2023: p. 113-119.

Long, J., et al., Macelignan protects against renal ischemia-reperfusion injury via inhibition of inflammation and apoptosis of renal epithelial cells. Cellular and Molecular Biology, 2020. 66(1): p. 55-59.

Ronco, C., R. Bellomo, and J.A.J.T.L. Kellum, Acute kidney injury. 2019. 394(10212): p. 1949-1964.

Al-Shibani, B. I. M., Kahaleq, M. A. A., Abosaooda, M., Mosa, A. K., Abdulhussein, M. A., & Hadi, N. R. (2020). Potential Nephroprotective

Effect of Valsartan in Renal Ischemia Reperfusion Injury Role of NFKBP65 Pathway in Rat. International Journal of Pharmaceutical Research

(09752366), 12(1). p. 928–936.

Hasanein, P., Rahdar, A., Barani, M., Baino, F., & Yari, S. (2021). Oil-inwater microemulsion encapsulation of antagonist drugs prevents renal ischemia-reperfusion injury in rats. Applied Sciences, 11(3), 1264.

Nedogoda, S., E. Buvailik, and V. Zhelezkin, Antioxidant action of moexipril in postmenopausal women with arterial hypertension. American Journal of Hypertension, 1999. 12(S4): p. 136-136.

Abbas, W., Altemimi, M., Qassam, H., Hameed, A. A., Zigam, Q., Abbas, L., ...& Hadi, N. (2022). Fimasartan ameliorates renal ischemia reperfusion injury via modulation of oxidative stress, inflammatory and apoptotic cascades in a rat model. Journal of Medicine and Life, 15(2), 241–251.

Alawadi, M.F., et al., Nephroprotective potential effect of U-50488H in renal ischemia reperfusion injury in adults Males rats’ model: Role of NRF2 pathway. International Journal of Pharmaceutical Research, 2020. 12(2).




How to Cite

Alsaaty, E. H., & Janabi, A. M. (2024). Moexipril Improves Renal Ischemia/Reperfusion Injury in Adult Male Rats. Journal of Contemporary Medical Sciences, 10(1).